

Risk of myocarditis following BNT162b2 and ChAdOx1 COVID-19  
vaccinations


## **Supplementary Figure 1: Patient age distribution**

TO BE UPDATED


## **Supplementary Figure 2: Dose 1 replication in Wales**

TO BE UPDATED


### Supplementary Figure 3: Interactions, by sex




## Supplementary Figure 4: Interactions, by age group



## Supplementary Figure 5: Estimates, by prior history



## Supplementary Figure 6: Estimates for pericarditis



**Supplementary Table 1a: Estimates, dose 1**

exposure	term	estimate	conf.low	conf.high	p.value	extended_fup	events
BNT162b2	NA	NA	NA	NA	NA	TRUE	55
BNT162b2	NA	NA	NA	NA	NA	FALSE	27
BNT162b2	NA	NA	NA	NA	NA	FALSE	120
BNT162b2	NA	NA	NA	NA	NA	TRUE	201
ChAdOx1-S	NA	NA	NA	NA	NA	TRUE	67
ChAdOx1-S	NA	NA	NA	NA	NA	FALSE	66
ChAdOx1-S	NA	NA	NA	NA	NA	FALSE	201
ChAdOx1-S	NA	NA	NA	NA	NA	TRUE	293

**Supplementary Table 1b: Estimates, dose 2**

exposure	term	estimate	conf.low	conf.high	p.value	extended_fup	events
BNT162b2	NA	NA	NA	NA	NA	TRUE	61
BNT162b2	NA	NA	NA	NA	NA	FALSE	13
BNT162b2	NA	NA	NA	NA	NA	FALSE	33
BNT162b2	NA	NA	NA	NA	NA	TRUE	516
ChAdOx1-S	NA	NA	NA	NA	NA	TRUE	42
ChAdOx1-S	NA	NA	NA	NA	NA	FALSE	16
ChAdOx1-S	NA	NA	NA	NA	NA	FALSE	17
ChAdOx1-S	NA	NA	NA	NA	NA	TRUE	765

**Supplementary Table 2: Dose 1 replication in Wales**

TO BE UPDATED

**Supplementary Table 3: Interactions, by age group**

age_group	dose	exposure	estimate	conf.low	conf.high	p.value
<40	Dose 1	BNT162b2	2.22	1.50	3.30	0.00
<40	Dose 1	BNT162b2	1.13	0.86	1.48	0.38
<40	Dose 1	BNT162b2	2.13	0.89	5.10	0.09
<40	Dose 1	BNT162b2	1.41	0.83	2.41	0.21
<40	Dose 1	ChAdOx1-S	2.84	1.67	4.81	0.00
<40	Dose 1	ChAdOx1-S	1.47	1.00	2.15	0.05
<40	Dose 1	ChAdOx1-S	2.78	1.63	4.77	0.00
<40	Dose 1	ChAdOx1-S	1.83	1.23	2.72	0.00
40-69	Dose 1	BNT162b2	0.62	0.32	1.19	0.15
40-69	Dose 1	BNT162b2	1.43	1.10	1.85	0.01
40-69	Dose 1	BNT162b2	0.60	0.30	1.21	0.16
40-69	Dose 1	BNT162b2	1.38	1.03	1.84	0.03
40-69	Dose 1	ChAdOx1-S	1.04	0.72	1.49	0.84
40-69	Dose 1	ChAdOx1-S	1.44	1.16	1.79	0.00
40-69	Dose 1	ChAdOx1-S	0.97	0.67	1.41	0.88
40-69	Dose 1	ChAdOx1-S	1.23	0.94	1.61	0.12
70+	Dose 1	BNT162b2	0.73	0.39	1.35	0.31
70+	Dose 1	BNT162b2	0.87	0.54	1.39	0.55
70+	Dose 1	BNT162b2	0.74	0.40	1.37	0.34
70+	Dose 1	BNT162b2	0.75	0.45	1.24	0.27
70+	Dose 1	ChAdOx1-S	0.86	0.45	1.65	0.66
70+	Dose 1	ChAdOx1-S	1.21	0.71	2.09	0.48
70+	Dose 1	ChAdOx1-S	0.76	0.39	1.48	0.42
70+	Dose 1	ChAdOx1-S	0.86	0.51	1.45	0.57

**Supplementary Table 4: Interactions, by sex**

sex	dose	exposure	estimate	conf.low	conf.high	p.value
Male	Dose 1	BNT162b2	1.26	0.87	1.83	0.22
Male	Dose 1	BNT162b2	1.31	1.07	1.60	0.01
Male	Dose 1	BNT162b2	0.51	0.26	1.00	0.05
Male	Dose 1	BNT162b2	1.17	0.88	1.54	0.28
Male	Dose 1	ChAdOx1-S	1.27	0.92	1.76	0.15
Male	Dose 1	ChAdOx1-S	1.28	1.05	1.56	0.01
Male	Dose 1	ChAdOx1-S	1.20	0.86	1.67	0.29
Male	Dose 1	ChAdOx1-S	1.16	0.92	1.46	0.22
Male	Dose 2	BNT162b2	1.48	1.03	2.14	0.03
Male	Dose 2	BNT162b2	0.83	0.64	1.07	0.15
Male	Dose 2	BNT162b2	0.37	0.15	0.93	0.03
Male	Dose 2	BNT162b2	0.56	0.29	1.09	0.09
Male	Dose 2	ChAdOx1-S	0.87	0.58	1.29	0.48
Male	Dose 2	ChAdOx1-S	0.77	0.56	1.05	0.10
Male	Dose 2	ChAdOx1-S	1.26	0.68	2.32	0.46
Male	Dose 2	ChAdOx1-S	1.04	0.49	2.21	0.92
Female	Dose 1	BNT162b2	1.29	0.84	1.98	0.24
Female	Dose 1	BNT162b2	1.06	0.80	1.39	0.68
Female	Dose 1	BNT162b2	1.19	0.73	1.94	0.48
Female	Dose 1	BNT162b2	0.94	0.65	1.36	0.76
Female	Dose 1	ChAdOx1-S	1.19	0.76	1.84	0.44
Female	Dose 1	ChAdOx1-S	1.42	1.08	1.86	0.01
Female	Dose 1	ChAdOx1-S	0.98	0.62	1.53	0.93
Female	Dose 1	ChAdOx1-S	0.95	0.69	1.32	0.78
Female	Dose 2	BNT162b2	0.93	0.53	1.65	0.81
Female	Dose 2	BNT162b2	0.87	0.61	1.23	0.42
Female	Dose 2	BNT162b2	0.72	0.31	1.70	0.46
Female	Dose 2	BNT162b2	0.93	0.46	1.91	0.85
Female	Dose 2	ChAdOx1-S	0.34	0.17	0.69	0.00
Female	Dose 2	ChAdOx1-S	0.67	0.45	1.01	0.05
Female	Dose 2	ChAdOx1-S	0.46	0.14	1.56	0.21
Female	Dose 2	ChAdOx1-S	1.56	0.68	3.61	0.29

**Supplementary Table 5a: Heterogeneity p-values, dose 1**

TO BE UPDATED

**Supplementary Table 5b: Heterogeneity p-values, dose 2**

TO BE UPDATED

**Supplementary Table 6: Estimates, by prior history**

prior_covid	dose	exposure	estimate	conf.low	conf.high	p.value
No	Dose 1	BNT162b2	0.82	0.55	1.23	0.33
No	Dose 1	BNT162b2	1.07	0.85	1.34	0.56
No	Dose 1	ChAdOx1-S	1.12	0.85	1.47	0.42
No	Dose 1	ChAdOx1-S	1.09	0.90	1.32	0.39
No	Dose 2	BNT162b2	0.54	0.28	1.02	0.06
No	Dose 2	BNT162b2	0.69	0.42	1.15	0.16
No	Dose 2	ChAdOx1-S	0.88	0.49	1.57	0.66
No	Dose 2	ChAdOx1-S	1.07	0.60	1.91	0.83
Yes	Dose 1	BNT162b2	1.33	0.18	9.91	0.78
Yes	Dose 1	BNT162b2	1.02	0.34	3.04	0.98
Yes	Dose 1	ChAdOx1-S	1.69	0.47	5.98	0.42
Yes	Dose 1	ChAdOx1-S	1.07	0.41	2.78	0.88
Yes	Dose 2	BNT162b2	0.00	0.00	0.00	0.00
Yes	Dose 2	BNT162b2	0.90	0.14	5.97	0.91
Yes	Dose 2	ChAdOx1-S	1.15	0.27	4.99	0.85
Yes	Dose 2	ChAdOx1-S	2.07	0.49	8.72	0.32

**Supplementary Table 7: Estimates for pericarditis**

dose	exposure	term	estimate	conf.low	conf.high	p.value
Dose 1	BNT162b2	14+	0.90	0.36	2.26	0.83
Dose 1	BNT162b2	14+	1.46	1.01	2.11	0.05
Dose 1	BNT162b2	14+	0.13	0.02	0.92	0.04
Dose 1	BNT162b2	14+	1.39	0.97	1.99	0.07
Dose 1	BNT162b2	0-13	0.48	0.21	1.10	0.08
Dose 1	BNT162b2	14+	1.35	1.00	1.83	0.05
Dose 1	ChAdOx1-S	14+	1.53	1.01	2.33	0.05
Dose 1	ChAdOx1-S	14+	1.54	1.14	2.09	0.01
Dose 1	ChAdOx1-S	14+	1.41	0.92	2.16	0.12
Dose 1	ChAdOx1-S	14+	1.43	1.07	1.92	0.02
Dose 1	ChAdOx1-S	0-13	1.20	0.82	1.75	0.34
Dose 1	ChAdOx1-S	14+	1.37	1.06	1.76	0.02
Dose 2	BNT162b2	14+	0.48	0.14	1.62	0.24
Dose 2	BNT162b2	14+	0.53	0.19	1.52	0.24
Dose 2	BNT162b2	14+	0.73	0.30	1.76	0.48
Dose 2	BNT162b2	14+	0.96	0.44	2.09	0.92
Dose 2	BNT162b2	0-13	0.53	0.25	1.12	0.09
Dose 2	BNT162b2	14+	0.87	0.47	1.59	0.64
Dose 2	ChAdOx1-S	14+	1.27	0.60	2.68	0.54
Dose 2	ChAdOx1-S	14+	0.43	0.11	1.77	0.24
Dose 2	ChAdOx1-S	14+	1.23	0.62	2.44	0.55
Dose 2	ChAdOx1-S	14+	0.33	0.10	1.09	0.07
Dose 2	ChAdOx1-S	0-13	1.12	0.61	2.03	0.72
Dose 2	ChAdOx1-S	14+	0.71	0.35	1.42	0.33